Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous vs Pulsatile Apomorphine in Parkinson's Disease
NCT00758368Phase 2Withdrawn
- Sponsor
- Oregon Health & Science University
- Start
- Mar 2009
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apomorphine in Parkinson's disease (PD) (2 arms), sponsored by Oregon Health & Science University. Primary endpoint: Change in dyskinesia severity and duration during the levodopa infusion at 6 months. Planned start Mar 2009; status: withdrawn.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00758368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00758368.